D. Western Therapeutics Institute, Inc.
4576.TJPXHealthcareBiotechnology
Latest quote
¥88.00
¥0.00 · 0.00%
4576.T company overview
Regular session · JST · Market data may be delayed.
Company profile
Company websiteD. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- JP
- CEO
- Yuichi Hidaka
- Listed since
- Oct 23, 2009
- Employees
- 19
Market position
Day range
Current ¥88.00
52-week range
Current ¥88.00
- Open
- ¥88.00
- Previous close
- ¥88.00
- Volume
- 168.6K
- 0.52× average
- Average volume
- 321.64K
- Average daily volume
- Market cap
- 5.06B JPY
- Beta
- -0.01
- Market reference 1
- 50-day average
- ¥77.16
- +14.05% above average
- 200-day average
- ¥90.59
- -2.86% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 3.5B JPY
- P/E (TTM)
- -7.39×
- P/B (TTM)
- 3.59×
- P/S (TTM)
- 20.43×
- EV / EBITDA
- -6.11×
- Earnings yield
- -13.74%
- Free cash flow yield
- -10.79%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 80.49%
- Operating margin
- -252.02%
- Net margin
- -257.89%
- Return on equity
- -44.03%
- Return on assets
- -29.14%
- Return on invested capital
- -30.02%
Financial health
- Debt / equity
- 0.41×
- Current ratio
- 9.91×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 387.62M JPY | 471.58M JPY | 428.36M JPY | 448.1M JPY | 414.42M JPY |
| Cost of goods sold | 86.38M JPY | 46.84M JPY | 36.67M JPY | 27.57M JPY | 20.1M JPY |
| Gross profit | 301.24M JPY | 424.74M JPY | 391.7M JPY | 420.53M JPY | 394.33M JPY |
| Research and development | 669.78M JPY | 1.37B JPY | 930.51M JPY | 469.56M JPY | 316.16M JPY |
| Selling, general, and administrative | 251.34M JPY | 265M JPY | 258M JPY | 255M JPY | 248M JPY |
| Operating expenses | 921.11M JPY | 1.63B JPY | 1.19B JPY | 726.45M JPY | 565.97M JPY |
| Interest income | 2.06M JPY | 76K JPY | 10K JPY | 25K JPY | 21K JPY |
| Interest expense | 8.82M JPY | 5.21M JPY | 2.49M JPY | 3.15M JPY | 4.42M JPY |
| Depreciation and amortization | 47.52M JPY | 49.33M JPY | 48.72M JPY | 46.37M JPY | 45.26M JPY |
| Operating income | −619.87M JPY | −1.21B JPY | −798.56M JPY | −305.91M JPY | −171.65M JPY |
| Net income | −632.09M JPY | −1.29B JPY | −812.41M JPY | −429.69M JPY | −149M JPY |
Company facts updated Aug 24, 2026.
4576.T peers
Continue in GoAI
Research 4576.Tresearch.disclaimer